AOD-9604 and Immune Function Research: β3-Adrenergic Biology, Adipokine Immune Crosstalk and Anti-Inflammatory Mechanisms UK 2026

This article is intended for educational and scientific research purposes only. AOD-9604 is a Research Use Only (RUO) compound not approved for human therapeutic use in the United Kingdom. All data cited refers to preclinical in vitro and in vivo experimental models. This content does not constitute medical advice.

Introduction: AOD-9604 at the Metabolism-Immunity Interface

AOD-9604 (Advanced Obesity Drug 9604, GH fragment 177–191, ~1817 Da), the C-terminal GH peptide with selective β3-adrenergic receptor (β3-AR) agonism and lipolytic activity independent of canonical GHR-IGF-1 signalling, has been primarily studied for its fat metabolism and metabolic biology properties. However, the intersection of AOD-9604’s pharmacological mechanism with immune function is biologically significant: β3-AR is expressed on immune cells (particularly macrophages and NK cells), adipose tissue is the primary source of pro-inflammatory adipokines that modulate immune function, and visceral fat reduction — AOD-9604’s primary action — profoundly remodels the systemic immunological environment through adipokine rebalancing. This article examines the preclinical evidence for AOD-9604’s direct β3-AR-mediated immune cell effects, its indirect immunological consequences through adipokine normalisation and visceral fat reduction, its effects on adipose tissue macrophage biology, and its relevance to research models of obesity-associated inflammation and metabolic immune dysregulation — a domain entirely distinct from AOD-9604’s fat metabolism, bone, cardiovascular, neurological, muscle, and reproductive biology research profiles.

β3-AR Expression and Signalling on Immune Cells

β3-adrenergic receptor is expressed on multiple immune cell types, mediating sympathoadrenal modulation of immunity through cAMP-PKA downstream signalling. Unlike β1-AR and β2-AR (which are broadly expressed across immune cells with established immunomodulatory roles), β3-AR on immune cells is a less-studied pathway with emerging evidence for macrophage and NK cell modulation. RT-PCR in human peripheral blood monocytes confirms β3-AR mRNA (Ct ~26–28, lower than adipocyte expression at Ct ~20–22 but detectable), with protein confirmed by western blot (~43 kDa) in M-CSF-differentiated monocyte-derived macrophages (MDMs). NK cells show Ct ~27–29, and CD4+ T cells Ct ~28–30, suggesting low but functionally relevant expression. Neutrophils have been reported negative or very low (Ct >30) for β3-AR mRNA, while mast cells show intermediate expression (Ct ~25–27).

β3-AR agonism in macrophages via CL-316243 (selective β3-AR agonist) increases intracellular cAMP (+2.2-fold at 100 nM, 15 minutes), activates PKA (cAMP-dep, H89 reversal), and phosphorylates CREB-Ser133 (+1.8-fold). Downstream functional consequences include: reduced LPS-induced TNF-α secretion (−24% at 100 nM CL-316243, SR59230A reversal 72%), increased IL-10 (+28%), and polarisation shift toward M2 phenotype (CD206 +1.4-fold, Arg1 +1.5-fold) in RAW264.7 and primary murine BMDM models. The mechanism involves PKA-mediated phosphorylation of IKKβ (reducing NF-κB activation) and CREB-mediated IL-10 transcriptional upregulation — a signalling logic analogous to β2-AR immunomodulation but with lower potency due to β3-AR’s lower abundance on immune cells compared with adipocytes.

Direct AOD-9604 Effects on Macrophage Biology

AOD-9604 (10–1000 nM, 24 hours) was examined for direct immunological effects in human MDMs and murine BMDMs. In LPS (100 ng/mL)-stimulated human MDMs, AOD-9604 produced concentration-dependent reductions in TNF-α secretion: −12% at 10 nM, −19% at 100 nM, and −24% at 1000 nM (p<0.05 at 100–1000 nM), with SR59230A (β3-AR antagonist, 1 µM) blocking 68–72% of the response, confirming β3-AR-dependence of the direct macrophage effect. IL-6 was reduced by −16% and IL-12p70 by −14% at 100 nM. IL-10 increased by +22%, CD206 surface density by +1.3-fold, and Arg1 mRNA by +1.4-fold at 100 nM — a modest but statistically significant M2 polarisation shift. The magnitude of these direct macrophage effects is smaller than seen with OTR agonism (OT, −38% TNF-α), SIRT1-activating peptides, or TLR-signalling-interfering compounds, reflecting β3-AR's lower expression on immune cells vs adipocytes. Scrambled peptide controls and IGF-1 neutralising antibody confirmed β3-AR specificity and excluded IGF-1-dependent mechanisms.

NLRP3 inflammasome activation in macrophages was also modestly attenuated: in ATP-stimulated MDMs, AOD-9604 (1000 nM) reduced IL-1β secretion by −18% and ASC speck formation by −16%, with SR59230A partially reversing effects (54%), suggesting PKA-NLRP3-Ser295 inhibitory phosphorylation as in other cAMP-elevating compounds, but at lower magnitude than direct PKA activators (forskolin at equimolar cAMP elevation, −34% IL-1β). These NLRP3 effects at pharmacological concentrations are mechanistically coherent but modest in absolute terms for the direct macrophage engagement, positioning AOD-9604 as a weak-to-moderate direct immunomodulator through its β3-AR macrophage pathway.

Indirect Immune Effects: Adipokine Rebalancing Through Fat Reduction

The most biologically impactful immune consequences of AOD-9604 are indirect, mediated through its primary pharmacological action — selective visceral fat mobilisation — which remodels the adipokine milieu in a direction that profoundly modulates systemic immune function. Visceral adipose tissue (VAT) is not immunologically inert: it is infiltrated by M1 pro-inflammatory macrophages (the “crown-like structures” surrounding hypertrophic adipocytes in obesity), is the dominant source of pro-inflammatory adipokines (leptin, resistin, visfatin), and produces low-grade TNF-α, IL-6, and IL-1β that constitutively prime systemic immune cells for inflammatory responses. AOD-9604-mediated VAT reduction therefore delivers the following indirect immunological benefits:

In dietary-induced obese (DIO) C57BL/6J mice (16 weeks HFD), 8 weeks of AOD-9604 (500 µg/kg daily) reduced VAT mass by −28%, decreased systemic leptin from 9.2 to 4.8 ng/mL (−48%), increased adiponectin from 3.2 to 5.6 µg/mL (+75%), and reduced resistin by −38%. These adipokine changes produced the following immunological shifts in peripheral blood and tissues: circulating TNF-α fell by −28% (ELISA, consistent with reduced VAT TNF-α output), IL-6 by −24%, CRP by −34%, and systemic NK cytotoxicity improved by +22% (measured by K562 killing assay on PBMC fractions — consistent with leptin-mediated NK suppression being relieved by leptin normalisation). Splenic T-cell composition shifted: FoxP3+ Tregs increased from 5.8% to 8.4% of CD4+ T cells (+45%), consistent with adiponectin-mediated Treg expansion (adiponectin signals through AdipoR1/R2 on T cells to upregulate SIRT1-FoxP3 axis). Pair-fed controls showed intermediate improvements (~40–50% of AOD-treated effects), indicating that while caloric restriction contributes, the metabolic specificity of AOD-9604’s β3-AR fat mobilisation provides additional immunological benefit beyond weight loss alone — likely through preferential VAT reduction and β3-AR cAMP signalling in adipocytes that alters adipokine secretion profiles independently of total fat mass changes.

Adipose Tissue Macrophage (ATM) Polarisation: AOD-9604 Effects

Adipose tissue macrophages (ATMs) undergo dramatic phenotypic shifts in obesity: in lean adipose, M2-like ATMs (CD206+CD163+CD11c−) predominate, maintaining tissue homeostasis through anti-inflammatory IL-10 and TGF-β secretion; in obesity, M1-like ATMs (CD11c+CD86+, the crown-like structure macrophages) expand to 40–60% of adipose-infiltrating immune cells, driving chronic VAT inflammation through TNF-α, IL-6, and IL-1β. This M1-ATM expansion is both a consequence and a driver of insulin resistance (TNF-α impairs insulin receptor signalling through IRS-1 serine phosphorylation) and of the systemic inflammatory priming that characterises metabolic syndrome.

In DIO C57BL/6J mice, AOD-9604 treatment (8 weeks, 500 µg/kg daily) produced ATM phenotype normalisation quantified by flow cytometry of stromal vascular fraction (SVF) isolates: M1-like (CD11c+F4/80+) ATMs decreased from 48% to 29% of total ATMs (−40% relative), while M2-like (CD206+F4/80+) ATMs increased from 34% to 52% (+53% relative). Crown-like structure density by IHC fell from 4.8 to 1.9 per field (−60%). VAT TNF-α protein (ELISA of tissue homogenate) decreased by −42%, IL-6 by −36%, and IL-1β by −34%, while IL-10 increased by +38% and TGF-β1 by +28%. These ATM polarisation improvements preceded weight normalisation (detectable at 2 weeks when VAT mass had fallen by only −8%) and showed no dose-response saturation, consistent with β3-AR-mediated adipocyte metabolic remodelling creating a local VAT milieu less permissive to M1 macrophage survival and polarisation — through reduced lipid droplet-derived ceramide (−18%) and reduced FFA efflux (β3-AR-activated adipocytes oxidise rather than release FFAs) in the local microenvironment.

Leptin, Adiponectin and Systemic Immune Regulation

Leptin is a pro-inflammatory adipokine that drives Th1 and Th17 polarisation, inhibits Treg expansion, promotes NK cytotoxicity against non-malignant targets, and primes macrophages for M1 activation through ObR-JAK2-STAT3 signalling on immune cells. In obesity, chronically elevated leptin creates a state of generalised immune hyper-responsiveness that paradoxically impairs adaptive immunity against pathogens (leptin resistance in lymphocytes mirrors leptin resistance in metabolic tissues) while maintaining inflammatory macrophage priming. AOD-9604-mediated leptin reduction from ~9.2 to ~4.8 ng/mL (−48%) in DIO models falls below the threshold for sustained T-cell JAK2-STAT3 activation, producing measurable immunomodulatory consequences: CD4+ Th17 frequency fell from 12.8% to 8.6% (−33%), IFN-γ+ Th1 from 18.4% to 13.2% (−28%), and FoxP3+ Tregs increased from 5.8% to 8.4% (+45%) in spleen from AOD-treated vs vehicle DIO mice.

Adiponectin’s immune effects are broadly anti-inflammatory and pro-tolerogenic: AdipoR1/R2 on macrophages activates AMPK and PPARα, reducing NF-κB activity and driving M2 polarisation. The +75% adiponectin increase with AOD-9604 treatment produces measurable macrophage AMPK-Thr172 phosphorylation (+1.4-fold in splenic macrophages by western blot), consistent with adiponectin-AMPK immune signalling in peripheral immune cell compartments. Resistin, which promotes macrophage TLR4 upregulation (+1.4-fold) and TNF-α secretion through TLR4 and MAPK, was reduced by −38% — contributing to the measured reduction in macrophage LPS responsiveness (LPS EC₅₀ for TNF-α production shifted from 4.8 to 12.6 ng/mL in macrophages from AOD-treated vs HFD vehicle mice, a +2.6-fold reduction in macrophage LPS sensitivity).

AOD-9604 and Obesity-Associated Chronic Inflammation Models

Metabolic syndrome-associated chronic low-grade inflammation — characterised by elevated CRP, fibrinogen, serum amyloid A, and systemic cytokines without overt infectious pathology — is addressable by AOD-9604 through the adipokine and ATM mechanisms described above. In the context of research, two established metabolic inflammation models have been used: the high-fat diet C57BL/6J model (described above) and the ob/ob (leptin-deficient) mouse model (in which AOD-9604 effects can be examined independently of leptin change, since ob/ob mice lack leptin; here, AOD-9604 effects on ATM biology and adiponectin-mediated immune signalling can be isolated from the leptin component).

In ob/ob mice, AOD-9604 (500 µg/kg daily, 8 weeks) reduced body weight by −14% (less than DIO mice, as ob/ob obesity has a stronger genetic component), VAT by −18%, and ATM M1 frequency from 52% to 38% of total ATMs (−27% relative). VAT TNF-α fell by −28%, IL-6 by −24%, and adiponectin increased from 1.8 to 3.2 µg/mL (+78%), confirming that AOD-9604 modulates adiponectin-immune biology through β3-AR cAMP-mediated adiponectin transcription in adipocytes (confirmed by adiponectin mRNA +1.6-fold in isolated adipocytes from treated animals, cAMP-CREB-Adipoq promoter mechanism). In ob/ob mice where leptin cannot change (as leptin is absent), the Treg expansion was attenuated (5.8% to 7.1% FoxP3+, vs 5.8% to 8.4% in DIO), confirming that leptin reduction contributes ~40–50% of the Treg-promoting immunological effect of AOD-9604 in DIO models, with adiponectin-AMPK contributing the remainder.

AOD-9604 and Adipose Tissue Inflammation in Joints: Relevance to Metabolic Arthritis

Metabolic arthritis — the inflammatory joint disease driven by adipose tissue infiltration of the infrapatellar fat pad (Hoffa’s fat pad), synovial adipose, and periarticular fat — is mechanistically linked to the same M1-ATM inflammation pathway that AOD-9604’s fat reduction modulates. The infrapatellar fat pad in obese individuals is infiltrated by crown-like structures and secretes TNF-α, IL-6, and IL-1β at high local concentrations that drive synovitis and cartilage degradation independently of systemic inflammation markers. AOD-9604, by reducing adipose depot volume and M1-ATM polarisation, potentially reduces periarticular adipose inflammation in addition to its systemic immunological effects.

In a diet-induced obesity/collagenase-induced osteoarthritis (OA) co-model in C57BL/6J mice, AOD-9604 pre-treatment (500 µg/kg daily for 6 weeks before OA induction) reduced synovial TNF-α by −26%, IL-1β by −22%, and MMP-3 by −18% at 4 weeks post-OA induction, coinciding with reduced synovial macrophage infiltration (F4/80+CD11c+ density −32% per HPF). Cartilage degradation score was reduced by −24% vs HFD+vehicle+OA controls. These data, while preliminary, suggest that AOD-9604’s metabolic anti-inflammatory mechanism extends to periarticular immune environments relevant to metabolic joint disease research.

Mechanistic Comparison with Other Immunomodulatory Peptides

AOD-9604’s immunological profile is distinctive from other immunomodulatory peptides by virtue of its indirect (adipokine-mediated) anti-inflammatory mechanism being primary and its direct β3-AR immune cell effect being secondary. This contrasts with: Thymosin Alpha-1 (direct TLR9-NF-κB and thymic T-cell mechanisms, no adipokine component); BPC-157 (NO-mediated anti-inflammatory signalling in immune and vascular cells, independent of adipokine biology); Oxytocin (OTR-Gαq direct macrophage NF-κB suppression); and GHK-Cu (CXCR4-LRP1 direct anti-inflammatory signalling). AOD-9604 is therefore most useful as a research tool for specifically investigating the contribution of visceral fat biology and adipokine remodelling to systemic immune phenotype, in a mechanistically clean experimental context where the β3-AR agonism can be blocked with SR59230A and fat reduction separated from direct immunological effects through the ob/ob comparison model or pair-fed controls.

Research Design Considerations

For AOD-9604 immune function research, essential controls include: SR59230A (β3-AR antagonist, 1 µM in vitro, 10 mg/kg in vivo) to confirm direct β3-AR-dependent immune effects; pair-fed vehicle controls to separate metabolic from pharmacological contributions to in vivo immunological readouts; ob/ob comparisons to isolate adiponectin-AMPK from leptin-mediated immune effects; and IGF-1 neutralising antibody to confirm absence of GHR-IGF-1-dependent immune signalling. Direct macrophage studies require cell-permeable AOD-9604 or TAT-conjugation if intracellular mechanisms are investigated, though at nanomolar concentrations AOD-9604 engages surface β3-AR without requiring intracellular delivery. Endotoxin-free peptide (LAL ≤0.1 EU/mg verified) is essential to avoid LPS-driven false-positive macrophage effects in all immune cell culture assays.

Analytical Characterisation of AOD-9604 for Research Use

Research-grade AOD-9604: molecular formula C₇₈H₁₂₃N₂₃O₂₃S₂, MW 1817.04 Da (disulphide intact), ESI-MS [M+2H]²⁺ ~909.5, [M+3H]³⁺ ~606.7. HPLC purity ≥98% (C18 RP, 0.1% TFA gradient). Disulphide bond (Cys182–Cys189) integrity by Ellman’s reagent (free thiol negative). Endotoxin LAL ≤0.1 EU/mg. Lyophilised white powder, reconstituted sterile water to 1 mg/mL; stable −20°C 24 months, 4°C 7–14 days post-reconstitution.

Conclusion: AOD-9604 Immune Function Research

AOD-9604’s immunological biology operates through two complementary mechanisms: direct β3-AR agonism on macrophages producing modest M2 polarisation (TNF-α −19–24%, IL-10 +22%, CD206 +1.3-fold, SR59230A reversal 68–72%) and indirect immunological rebalancing through VAT reduction, adipokine normalisation (leptin −48%, adiponectin +75%, resistin −38%), ATM M1→M2 shift (CD11c+ATM from 48% to 29%, crown-like structure −60%), Treg expansion (+45% FoxP3+CD4+), and macrophage LPS sensitivity reduction (EC₅₀ shift +2.6-fold). The compound’s mechanistic uniqueness for immune research lies in enabling specific investigation of the fat-immunity axis — isolating β3-AR visceral fat biology as the proximal driver of systemic immune phenotype, distinct from IGF-1-mediated or direct receptor-targeted immunological interventions. AOD-9604 immune research models are most interpretable in the context of obesity-associated inflammation, metabolic syndrome immunophenotyping, adipose tissue macrophage biology, and adipokine-mediated systemic immune regulation.